Cancer takes hundreds of thousands of lives each year. Most cancer deaths result from the metastatic spread of drug-resistant cells, thus biomarkers capable of predicting tumor progression and therapeutic response are needed.
Liquid biopsy is a promising approach to characterize the tumor phenotype. EVs (exosomes) are potential sources of tumor biomarkers because they carry the same histological membrane markers as a tumor. However, a major challenge encountered when analyzing histological markers on EVs is the fact that the signal from histological markers is often beyond the detection limit of commonly used techniques.
Exosome Analytics develops high-sensitivity technologies and products for EVs profiling. Based on these technologies, we are developing diagnostic platforms for early cancer screening, tumor profiling and early detection of tumor relapse.
Company Details
- Employees
- 2
- Founded
- -
- Address
- 4 Rue Pierre Fontaine, Evry-Courcouronnes Cedex,91058,france
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- HQ
- Evry-Courcouronnes Cedex
Exosome Analytics Questions
Exosome Analytics's LinkedIn profile is https://fr.linkedin.com/company/exosome-analytics
Exosome Analytics has
2 employees.
View email and phone details for 2
employees at Exosome Analytics.
Exosome Analytics's industry is
Biotechnology Research
Exosome Analytics's top competitors are
Movalife Microrobotics,
One Biosciences,
Exosome Diagnostics, A Bio-Techne Brand,
Madecell,
Msinsight,
Fizimed,
Kyron.bio,
Gynea,
Benev Exosome Regenerative Complex,
Dalia.
Exosome Analytics's categories are Biotechnology Research
Exosome Analytics's founding year is 2021
